Hadeel Anwar Alsarraje, Liqaa Khalel Alhyali
Vol. 14, Jul-Dec 2022
Osteoporosis is the most problem of women's bone disease, it has a multitude of causes, including menopause. It affects about one in three women. Before a fracture, osteoporosis does not exhibit any clinical symptoms. Important pathology is brought on by fractures. Postmenopausal osteoporosis can be avoided with early diagnosis of this condition before fractures happen; Menopausal hormone therapy (MHT) significantly reduces the fracture risk in all body bones by halting bone loss and degeneration of bone microstructure. The fast bone loss brought on by declining estrogen peaks in the first two to three years following menopause. Even in women with modest fracture risk, MHT is the only anti-osteoporosis medication that has been shown to be effective regardless of baseline risk. There is no rationale for using specific, efficient drugs to treat osteoporosis, making MHT the first option for maintaining bone health in women. It is also advisable to evaluate the advantages and risks of MHT. MHT has become the leading therapeutic choice for preserving bone health in early postmenopausal women.